Drug Development

Nestlé invests $145M in Aimmune’s food allergy R&D work, taking the head seat at the deal table

Greg Behar, CEO, Nestlé Health Science

Greg Behar, CEO, Nestlé Health Science

Nestlé Health Science is making another big investment in an emerging biotech company. The Brisbane, CA-based Aimmune $AIMT is selling a whopping $145 million stake in the company to Nestlé Health Science.

The investment gives Nestlé 15% of the biotech — 7.6 million shares at $19.20 a share — and creates a new collaboration in which Nestlé will provide “ongoing scientific, regulatory, and commercial expertise and advice” on the biotech’s development of new therapies for food allergies. Nestle, meanwhile, also gets an option on getting the first crack at partnering with Aimmune on its oral food allergy treatments.

That includes Aimmune’s lead Phase III program for AR101, a biologic in development for peanut allergies.

Nestlé Health Science has been a busy biotech investor, buying into companies like Pronutria, which has been developing a new way to develop proteins that can deliver therapeutic doses of amino acids to the bloodstream. It’s also invested in Seres $MCRB, another Cambridge, MA-based biotech. And there was a €100 million deal for DBV Technologies back in May to help develop a diagnostic for pediatric milk allergies.

Said Greg Behar, CEO of Nestlé Health Science:

“Nestlé Health Science is investing and innovating to change the approach to food allergy management, with integrated approaches from diagnostics (Dx) to nutrition solutions (Nx) and now biologics (Rx), where Aimmune’s proprietary approach has transformational potential in the lives of patients and families.”


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

BioNJ CEO Summit 2017

Immuno Oncology 360